Julian Symons
Directeur Technique/Scientifique/R&D chez ALIGOS THERAPEUTICS, INC.
Fortune : 322 344 $ au 30/04/2024
Postes actifs de Julian Symons
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ALIGOS THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/05/2018 | - |
Historique de carrière de Julian Symons
Anciens postes connus de Julian Symons
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/01/2013 | 01/04/2018 |
Formation de Julian Symons
| University of Central Lancashire | Undergraduate Degree |
| York University | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 3 |
| Royaume-Uni | 2 |
| Canada | 2 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 3 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALIGOS THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Alios BioPharma, Inc.
Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Alios BioPharma, Inc. operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases. It also develops proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including RSV, influenza, rhinovirus and emerging viral diseases. The firm offers VX-135, a uridine nucleotide analog for the treatment of chronic hepatitis C. The company was founded by Leonid N. Beigelman, Lawrence M. Blatt and John R. Donovan in 2008 and is headquartered in San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Julian Symons
- Expérience
